The abstract is read at the publisher; the summary is JClub's.
Hospital-wide inpatient first-tier rapid exome/genome sequencing in 1000 children achieved a 43.1% diagnostic rate in non-ICU ward admissions, with 65.2% for faltering growth.
- Why it matters: The study addresses how rapid first-tier sequencing performs beyond ICU settings and across clinical phenotypes after broad hospital implementation.
- What they did: In a single-center 3.7-year period (May 5, 2022 to January 26, 2026), diagnostic yield of inpatient first-tier rES/rGS was assessed across units and phenotypes at consultation.
- The result: Diagnostic rates were similar to prior ICU reports (27.4%-36.9%), and the findings support first-tier rES/rGS for hospitalized children outside ICU and potentially for faltering growth workups.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.